PR
TEVA icon

Payden & Rygel’s Teva Pharmaceuticals TEVA Stock Holding History

Payden & Rygel’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-211,600
Closed -$9.74M – 116
2016
Q3 		$9.74M Buy
+211,600
New +$11M 0.98% 44
2016
Q1 		– Sell
-762
Closed -$50K – 204
2015
Q4 		$50K Buy
+762
New +$47.1K 0.01% 112

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Payden & Rygel's TEVA Position: Q4 2016 in Review

Payden & Rygel sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 211,600 shares — an estimated $9.74M sold.

Payden & Rygel first reported a position in TEVA in Q4 2015 and held it in 2 quarters. The position peaked at $9.74M in Q3 2016. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • Payden & Rygel reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Payden & Rygel sold 211,600 Teva Pharmaceuticals shares in Q4 2016, an estimated $9.74M.
  • Payden & Rygel first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Payden & Rygel's Teva Pharmaceuticals position peaked at $9.74M in Q3 2016.
  • 737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Payden & Rygel's 13F filing for Q4 2016, filed 8 Feb 2017.